KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.
Gajiwala, K.S., Wu, J.C., Christensen, J., Deshmukh, G.D., Diehl, W., DiNitto, J.P., English, J.M., Greig, M.J., He, Y.A., Jacques, S.L., Lunney, E.A., McTigue, M., Molina, D., Quenzer, T., Wells, P.A., Yu, X., Zhang, Y., Zou, A., Emmett, M.R., Marshall, A.G., Zhang, H.M., Demetri, G.D.(2009) Proc Natl Acad Sci U S A 106: 1542-1547
- PubMed: 19164557 
- DOI: 10.1073/pnas.0812413106
- Primary Citation of Related Structures:  
3G0E, 3G0F - PubMed Abstract: 
Most gastrointestinal stromal tumors (GISTs) exhibit aberrant activation of the receptor tyrosine kinase (RTK) KIT. The efficacy of the inhibitors imatinib mesylate and sunitinib malate in GIST patients has been linked to their inhibition of these mutant KIT proteins ...